Car T-Cell Therapy
The case for CAR T cells as earlier treatment requires more evidence
The development of chimeric antigen receptor T cells has provided hope for patients with hematologic malignancies, but their commercial use has been limited to an option of last resort.
FDA clears IND application for allogeneic CAR-T to treat advanced multiple myeloma
The FDA cleared an investigational new drug application for ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma, according to the agent’s manufacturer.
FDA grants RMAT designation to allogeneic CAR-T for advanced multiple myeloma
The FDA granted regenerative medicine advanced therapy designation to ALLO-715, an allogeneic chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma, according to the manufacturer.
Lenzilumab before CAR-T induces high response rates without severe toxicities
A combination of lenzilumab and axicabtagene ciloleucel induced an 83% overall response rate among patients with advanced diffuse large B-cell lymphoma, according to topline data released by the agent’s manufacturer.
Novel CAR-T shows ‘promising early signs of clinical efficacy’ for diffuse midline gliomas
Three of four patients who received an investigational chimeric antigen receptor T-cell therapy for diffuse midline glioma showed tumor regression and improvement in neurologic symptoms, according to early results of a phase 1 study.
Product composition, immune biomarkers linked to CAR-T efficacy
Product attributes appeared associated with more potent and durable responses to axicabtagene ciloleucel among patients with follicular lymphoma, according to an analysis of the ZUMA-5 trial.
Bispecific CAR-T shows early efficacy, ‘exceptional safety’ in advanced B-cell lymphoma
Four of five patients with relapsed or refractory B-cell lymphoma demonstrated complete response to an investigational anti-CD19/CD20 chimeric antigen receptor T-cell therapy, according to early data from a phase 1 trial.
First FDA-approved CAR T-cell therapy for multiple myeloma hailed as ‘game changer’
Although it took a bit longer than expected, the first FDA approval of a chimeric antigen receptor T-cell therapy for advanced multiple myeloma will have a major impact on clinical practice, according to experts.
CAR-T provides superior efficacy for multiple myeloma at higher cost, report states
Chimeric antigen receptor T-cell therapies demonstrated greater clinical effectiveness than standard care among patients with heavily pretreated multiple myeloma, according to a report by the Institute for Clinical and Economic Review.
FDA clears IND application for ‘controllable’ cell therapy to treat advanced multiple myeloma
The FDA cleared an investigational new drug application for ACLX-001, a chimeric antigen receptor T-cell therapy for adults with relapsed and refractory multiple myeloma, according to the agent’s manufacturer.